PCSK9 and myocardial infarction: The strategy of early administration of PCSK9-i after an MI event has quickly become an intensive field of research and there are two ongoing trials aiming to investigate the efficacy of evolocumab in this clinical scenario: the EVOLVE-MI (EVOLocumab Very Early After Myocardial Infarction) trial (NCT05284747) and the AMUNDSEN (Evolocumab or Normal Strategies to Reach LDL-C Objectives in Acute Myocardial Infarction Upbound to PCI) trials (NCT04951856).